Antibody treatment in multiple myeloma.

Abstract

Antibody therapy, which has become a critical option in the treatment of multiple myeloma (MM), includes monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies. Anti-CD38 and anti-SLAMF7 monoclonal antibodies were the first to enter the MM portfolio as treatment options for relapsed/ refractory MM. More recently, daratumumab has become important in the treatment of newly diagnosed MM, and a subcutaneous formulation has been approved. BCMA-targeted antibody-drug conjugates and bispecific antibodies, which are the newest antibody therapies to be investigated, provide additional therapeutic options for patients with heavily pretreated MM. This article reviews how antibody therapy has influenced the treatment of MM, describes the unique adverse event profiles of each relevant drug class, and explains how to incorporate antibody therapy into practice.

• Authors: Kathryn T Maples, Catherine Johnson, Sagar Lonial
• Journal: Clinical advances in hematology & oncology : H&O (Clin Adv Hematol Oncol) Vol. 19 Issue 3 Pg. 166-174 (Mar 2021) ISSN: 1543-0790 [Print] United States
• PMID: 33739965 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Bispecific
• Antineoplastic Agents, Immunological
• B-Cell Maturation Antigen
• Immunoconjugates
• SLAMF7 protein, human
• Signaling Lymphocytic Activation Molecule Family
• TNFRSF17 protein, human
• ADP-ribosyl Cyclase 1

Topics

• ADP-ribosyl Cyclase 1 (antagonists & inhibitors, immunology)
• Animals
• Antibodies, Bispecific (adverse effects, immunology, therapeutic use)
• Antineoplastic Agents, Immunological (adverse effects, immunology, therapeutic use)
• B-Cell Maturation Antigen (antagonists & inhibitors, immunology)
• Humans
• Immunoconjugates (adverse effects, immunology, therapeutic use)
• Multiple Myeloma (drug therapy, immunology)
• Signaling Lymphocytic Activation Molecule Family (antagonists & inhibitors, immunology)